Nursing Implications for the Lifelong Management of Tuberous Sclerosis Complex
Authors:
- Karen AgricolaKAKaren Agricola
- Cindy TudorCTCindy Tudor
- Darcy KruegerDKDarcy Krueger
- David Neal FranzDFDavid Neal Franz
- 1 August 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Neuroscience Nursing
- Vol. 45 (4) , 226-242
Abstract
Tuberous sclerosis complex (TSC) is a genetic disorder that can affect multiple organ systems, including the brain, heart, skin, kidney, and lung, by formation of benign hamartomas. It can be associated with autism, epilepsy, and other neurocognitive and behavioral disabilities. The incidence of TSC is approximately 1 in 6,000 live births, but it may be underdiagnosed. Mutations to either the TSC1 (coding for hamartin) or TSC2 (coding for tuberin) genes are present in 85% of patients with TSC. The TSC1/TSC2 protein dimer complex is a crucial inhibitory element in the mammalian target of rapamycin (mTOR) complex 1 pathway that regulates cell growth and proliferation. The manifestations of TSC usually require management over the entire life of the patient. Until recently, there were few options, other than surgical removal, for treating the symptoms of TSC related to growth of hamartomas. Increased understanding of the genetic cause of the disease and the underlying dysregulation of the mTOR pathway has led to clinical trials of mTOR inhibitors including sirolimus and everolimus. This article will review the various manifestations of TSC and describe treatment strategies, recommendations for surveillance, and use of mTOR inhibitors in their management.Keywords
This publication has 39 references indexed in Scilit:
- Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels DecreasePLOS ONE, 2011
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisNew England Journal of Medicine, 2011
- Characterizing sleep disorders of adults with tuberous sclerosis complex: A questionnaire-based study and reviewEpilepsy & Behavior, 2011
- The natural history of epilepsy in tuberous sclerosis complexEpilepsia, 2010
- The Natural History of Lymphangioleiomyomatosis: Markers of Severity, Rate of Progression and PrognosisLymphatic Research and Biology, 2010
- The tuberous sclerosis complexAnnals of the New York Academy of Sciences, 2010
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Current Management of Tuberous Sclerosis ComplexPediatric Drugs, 2008
- High Frequency of Pulmonary Lymphangioleiomyomatosis in Women With Tuberous Sclerosis ComplexMayo Clinic Proceedings, 2000
- Prevalence of tuberous sclerosis estimated by capture-recapture analysisThe Lancet, 1998